EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Genetic control of drug-induced recovery from murine visceral leishmaniasis



Genetic control of drug-induced recovery from murine visceral leishmaniasis



Journal of Pharmacy and Pharmacology 45(9): 795-798



The influence of host genetic background on the response to Leishmania donovani-infected mice to chemotherapy was studied using the H-2-d and H-2-b haplotypes on a BALB or a B10 genetic background. Animals were treated with free or liposomal sodium stibogluconate and parasite burdens in the liver, spleen and bone marrow were assessed. In all the mouse strains and their congenic derivatives examined, the liver responded best to therapy regardless of drug formulation, whilst the spleen and the bone marrow respectively were increasingly less responsive to chemotherapy. Treatment with free drug was more effective in congenic mice carrying the H-2-b haplotype than in those carrying the H-2-d haplotype and in mice carrying the same H-2 haplotype, animals from a BALB background were better responders than those from a B10 genetic background. Liposomal drug was more effective than free drug treatment in all four mouse strains and produced a similar suppression ( gt 99%, P lt 0.001) in liver parasite burdens to that obtained using a six times greater free drug dose. This liposomal drug dose was more effective than free drug in reducing bone marrow parasite burdens in all four mouse strains and equally (BALB/c mice) or more effective (P lt 0.01, BALB/B, B10 and B10.D2 strains) in reducing spleen parasite numbers. Liposomal drug, particularly in the B10 genetic background, effectively negated the H-2 dependent influences apparent using free sodium stibogluconate. These results are discussed in relation to the genetic factors which are known to control the course of L. donovani infection in mice.

(PDF 0-2 workdays service: $29.90)

Accession: 002390536

Download citation: RISBibTeXText

PMID: 7903366



Related references

Genetic control of recovery from visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene6(2): 147-151, 1982

Leishmaniasis in Liguria; epidemiology of 91 cases of visceral & cutaneous leishmaniasis; clinical characteristics of 41 cases of visceral leishmaniasis in children with recovery in a pediatric clinic. Annali Della Sanita Pubblica 17(3): 749-777, 1956

Studies on control of visceral leishmaniasis: Impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia and Brazil. American Journal of Tropical Medicine & Hygiene 59(1): 53-57, July, 1998

Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. American Journal of Tropical Medicine and Hygiene 59(1): 53-57, 1998

New therapy for visceral leishmaniasis. India licenses miltefosine, the first oral drug for visceral leishmaniasis. Weekly Epidemiological Record 77(25): 210-212, 2002

Morphine-induced neuroimmunomodulation in murine visceral leishmaniasis: the role(s) of cytokines and nitric oxide. Journal of Neuroimmune Pharmacology 2(4): 338-351, 2007

Genetic control of acquired resistance to visceral leishmaniasis in mice. Immunogenetics: 353-362, 1980

Genetic control of acquired resistance to visceral leishmaniasis in mice. Immunogenetics 10(4): 353-361, 2012

Studies on the control of visceral leishmaniasis: validation of the Falcon assay screening test--enzyme-linked immunosorbent assay (FAST-ELISA) for field diagnosis of canine visceral leishmaniasis. American Journal of Tropical Medicine and Hygiene 48(1): 1-8, 1993

Diet-induced obesity promotes systemic inflammation and increased susceptibility to murine visceral leishmaniasis. Parasitology 143(12): 1647-1655, 2016

Studies on the genetic control of visceral leishmaniasis in BALB/c mice by L. tropica. Genetic control of natural resistance to infection and malignancy Proc Internat Symp Can Soc Immunol, Montreal, Quebec, March 18-20-1980: 29-35, 1980

Post-kala-azar dermal leishmaniasis with visceral leishmaniasis, or a rare presentation of visceral leishmaniasis with extensive skin manifestations. International Journal of Dermatology 46(12): 1326-1326, 2008

Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. Journal of Immunology 146(8): 2763-2770, 1991

Concurrent visual diagnosis and susceptibility profiling of the first line drug against visceral leishmaniasis by plasmonic detection of PCR amplified genetic biomarker. Acta Tropica 152: 208-214, 2016

Multilocus microsatellite typing reveals a genetic relationship but, also, genetic differences between Indian strains of Leishmania tropica causing cutaneous leishmaniasis and those causing visceral leishmaniasis. Parasites & Vectors 7(): 123-123, 2014